KR950008493A - 유착 수용체 길항물질(iii) - Google Patents

유착 수용체 길항물질(iii) Download PDF

Info

Publication number
KR950008493A
KR950008493A KR1019940023840A KR19940023840A KR950008493A KR 950008493 A KR950008493 A KR 950008493A KR 1019940023840 A KR1019940023840 A KR 1019940023840A KR 19940023840 A KR19940023840 A KR 19940023840A KR 950008493 A KR950008493 A KR 950008493A
Authority
KR
South Korea
Prior art keywords
compound
formula
salt
radical
oxazolidin
Prior art date
Application number
KR1019940023840A
Other languages
English (en)
Other versions
KR100347849B1 (ko
Inventor
간트 요하힘
유라스찌크 호르스트
라다쯔 페터
부르찌거 한스
멜찌 구이도
베르노타트-다니엘로브스키 사빈
Original Assignee
위르겐 호이만, 라인하르트 슈틀러
메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위르겐 호이만, 라인하르트 슈틀러, 메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁 filed Critical 위르겐 호이만, 라인하르트 슈틀러
Publication of KR950008493A publication Critical patent/KR950008493A/ko
Application granted granted Critical
Publication of KR100347849B1 publication Critical patent/KR100347849B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

하기 일반식(I)의 신규한 옥사졸리디논 유도체 및 그의 생리학적으로 무해한 염은 피브리노겐이 상응하는 수용체에 결합하는 것을 억제하고 혈전증, 발작, 심근, 경색증, 염증, 동맥경화증, 골다공증 및 또는 종양을 치료하는데 유용할 수 있다.
상기식에서, R1은 비치환되거나 또는 CN, H2N-CH2-, A2N-CH2-, H2N-C(=NH)-, H2N-C(=NH)-NH-, H2N-C(=NH)-NH-CH2-, HO-NH-C(=NH)- 또는 HO-NH-C(=NH)-NH-에 의해 일치환 되는 페닐라디칼이고, X는 O, S, SO2, -NH- 또는 -NA-이고,
A는 탄소 원자수가 1내지 6개의 알킬이고, R2는 H, A, Li, Na, K, NH4또는 벤질이고, R3은 H 또는 (CH2)nCOOR2이고, E는 각각의 경우에 서로 독립적으로, CH 또는 N이고, Q는 O, S 또는 NH이고, m은 1,2또는 3이고, n은 0, 1, 2또는 3이다.

Description

유착 수용체 길항물질(Ⅲ)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(i)의 옥사졸리디노 유도체 및 그의 생리학적으로 무해한 염;
    상기식에서, R1은 비치환되거나 또는 CN, H2N-CH2-, A2N-CH2-, H2N-C(=NH)-, H2N-C(=NH)-NH-, H2N-C(=NH)-NH-CH2-, HO-NH-C(=NH)- 또는 HO-NH-C(=NH)-NH-에 의해 일치환 되는 페닐라디칼이고, X는 O, S, SO, SO2, -NH- 또는 -NA-이고,
    A는 탄소 원자수가 1내지 6개의 알킬이고, R2는 H, A, Li, Na, K, NH4또는 벤질이고, R3은 H 또는 (CH2)nCOOR2이고, E는 각각의 경우에 서로 독립적으로, CH 또는 N이고, Q는 O, S 또는 NH이고, m은 1,2또는 3이고, n은 0, 1, 2또는 3이다.
  2. 제1항에 있어서, 하기 화합물(a)내지 (d)중에서 선택되는 유도체; (a)3-p-아미디노페닐-5-(p-카복시메틸페녹시메틸)-옥사졸리딘-2-온; (b)3-p-아미노페닐-5-(p-메톡시카보닐메틸페녹시메틸)-옥사졸리딘-2-온 (c)3-p-아미노메틸페닐-5-(p-카복시메틸페녹시메틸)-옥사졸리딘-2-온 나트륨 염; (d)3-p-구아니디노메틸페닐-5-(p-카복시메틸페녹시메틸)-옥사졸리딘-2-온.
  3. 제1항에 따르는 일반식(I)의 거울상이성질체 화합물 또는 하나의 그의 염.
  4. 하기 일반식(II)의 화합물을 하기 일반식(Ⅲ)의 화합물과 반응시키거나, 또는 사기 일반식(IV)의 화합물 또는 그의 반응성 유도체중 하나를 카본산의 반응성 유도체와 반응시키거나, 또는 일반식(I), (R1=H2N-C(=NH)-NH-에 의해 일치환되는 페닐 라디칼)의 구아니다노 화합물을 제조하기 위하여, 일반식(I)에 상응하지만 라디칼 R1대신에 아니노페닐 그룹을 함유하는 아미노 화합물을 아미딘화제로 처리하거나, 또는 가용매 분해 또는 수소화 분해제로 처리하므로써, 일반식(I)의 화합물을 하나의 그의 작용성 유도체로부터 유리시키고/시키거나, 일반식(I)의 화합물에서, 라디칼 R1및/또는 B중 하나 또는 모두를 다른 라디칼 R1및/또는 B로 전환하고/하거나 일반식(I)의 화합물을 산 또는 염기로 처리하므로써 그의 염중 하나로 전환함을 특징으로 하는, 제1항에 따르는 일반식(I)의 화합물 및 또한 그의 염의 제조 방법;
    상기식에서, R1은 비치환되거나 또는 CN, H2N-CH2-, A2N-CH2-, H2N-C(=NH)-, H2N-C(=NH)-NH-, H2N-C(=NH)-NH-CH2-, HO-NH-C(=NH)- 또는 HO-NH-C(=NH)-NH-에 의해 일치환 되는 페닐라디칼이고, X는 O, S, SO, SO2, -NH- 또는 -NA-이고,
    A는 탄소 원자수가 1내지 6개의 알킬이고, R2는 H, A, Li, Na, K, NH4또는 벤질이고, R3은 H 또는 (CH2)n-COOR2이고, E는 각각의 경우에 서로 독립적으로, CH 또는 N이고, Q는 O, S 또는 NH이고, m은 1,2또는 3이고, n은 0, 1, 2또는 3이고, Z는 Cl, Br, I, OH또는 에스테르화된 반응성 OH그룹이고, Y는 OH, SH, NH2또는 OH 또는 SH로부터 유도될 수 있는 염과 유사한 라디칼이다.
  5. 제1항에 따르는 일반식(I)의 화합물 및/또는 그의 생리학적으로 무해한 염 중 하나를 적어도 하나의 고형, 액체 또는 반액체 부형제 또는 보조 물질과 함께 적합한 투여 형태로 제조함을 특징으로 하는, 약학적 제제의 제조방법.
  6. 제1항에 따르는 적어도 하나의 일반식(I)의 화합물 및/또는 그의 약학적으로 무해한 염 중 하나를 함유함을 특징으로 하는, 약학적 제제.
  7. 약물을 제조하기 위한, 제1항에 따르는 일반식(I)의 화합물, 또는 그의 약학적으로 무해한 염의 용도.
  8. 혈전증, 심근 경색증, 발작, 골다공증, 동맥경화증, 염증 및/또는 종양의 치료에서, 제1항에 따르는 일반식(I)의 화합물 또는 그의 약학적으로 무해한 염의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940023840A 1993-09-23 1994-09-22 유착수용체길항물질(iii) KR100347849B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4332384.7 1993-09-23
DE4332384A DE4332384A1 (de) 1993-09-23 1993-09-23 Adhäsionsrezeptor-Antagonisten III

Publications (2)

Publication Number Publication Date
KR950008493A true KR950008493A (ko) 1995-04-17
KR100347849B1 KR100347849B1 (ko) 2002-11-16

Family

ID=6498425

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940023840A KR100347849B1 (ko) 1993-09-23 1994-09-22 유착수용체길항물질(iii)

Country Status (21)

Country Link
US (3) US5561148A (ko)
EP (1) EP0645376B1 (ko)
JP (1) JPH07179441A (ko)
KR (1) KR100347849B1 (ko)
CN (1) CN1052227C (ko)
AT (1) ATE178599T1 (ko)
AU (1) AU682050B2 (ko)
CA (1) CA2132579A1 (ko)
CZ (1) CZ288819B6 (ko)
DE (2) DE4332384A1 (ko)
DK (1) DK0645376T3 (ko)
ES (1) ES2132295T3 (ko)
GR (1) GR3030512T3 (ko)
HU (1) HU217980B (ko)
NO (1) NO305203B1 (ko)
PL (1) PL180462B1 (ko)
RU (1) RU2125560C1 (ko)
SK (1) SK282134B6 (ko)
TW (1) TW381086B (ko)
UA (1) UA40590C2 (ko)
ZA (1) ZA947405B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313411A1 (de) * 1993-04-23 1994-10-27 Basf Ag 3-Halogen-3-hetarylcarbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
DE4429461A1 (de) * 1994-08-19 1996-02-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DK0710657T3 (da) * 1994-11-02 1999-05-25 Merck Patent Gmbh Adhæsionsreceptor-antagonister
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
KR100441334B1 (ko) * 1995-02-03 2004-10-20 파마시아 앤드 업존 캄파니 헤테로-방향족고리치환된페닐옥사졸리딘온항균제
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19601265A1 (de) 1996-01-16 1997-07-17 Bayer Ag 2-Oxo- und 2-Thio-1,2-dihydrochinolinyl-oxazolidinone
DE19601627A1 (de) 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
KR100504449B1 (ko) * 1996-07-25 2005-07-29 바이오겐 아이덱 엠에이 인코포레이티드 세포 유착 억제제
AU729488B2 (en) * 1996-08-29 2001-02-01 Merck & Co., Inc. Compositions and methods for administering integrin receptor antagonists
GB9812019D0 (en) * 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
EP1082323A2 (en) * 1998-06-05 2001-03-14 AstraZeneca UK Limited Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
AU2713500A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10159453A1 (de) * 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
US7141588B2 (en) * 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
PL372090A1 (en) * 2002-02-28 2005-07-11 Astrazeneca Ab Chemical compounds
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006029258A2 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
BRPI0514984A (pt) 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE502006009169D1 (en) 2005-10-04 2011-05-05 Bayer Schering Pharma Ag NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
AU2009206658A1 (en) * 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. 3,5-substituted-1,3-oxazolidin-2-one derivatives
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
US4602093A (en) * 1984-02-08 1986-07-22 Merck & Co., Inc. Novel substituted imidazoles, their preparation and use
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4005371A1 (de) * 1990-02-21 1991-08-22 Merck Patent Gmbh Oxazolidinone
DE4017211A1 (de) * 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
DE69329106T2 (de) * 1992-04-30 2001-03-22 Taiho Pharmaceutical Co Ltd Oxazolidinderivat und sein pharmazeutisch verträgliches salz
US5532225A (en) * 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
DK0623615T3 (da) * 1993-05-01 1999-12-13 Merck Patent Gmbh Adhæsionsreceptor-antagonister
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4324393A1 (de) * 1993-07-21 1995-01-26 Merck Patent Gmbh 4-Aryloxy- und 4-Arylthiopiperidinderivate
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
TW286317B (ko) * 1993-12-13 1996-09-21 Hoffmann La Roche
TW363051B (en) * 1995-08-31 1999-07-01 Mitsui Toatsu Chemicals Substituted amidine derivatives and platelet aggregation inhibitor containing the same

Also Published As

Publication number Publication date
TW381086B (en) 2000-02-01
HU9402724D0 (en) 1994-12-28
EP0645376A1 (de) 1995-03-29
DK0645376T3 (da) 1999-10-18
AU682050B2 (en) 1997-09-18
HUT71233A (en) 1995-11-28
NO943523D0 (no) 1994-09-22
DE59408068D1 (de) 1999-05-12
NO305203B1 (no) 1999-04-19
CZ288819B6 (cs) 2001-09-12
DE4332384A1 (de) 1995-03-30
CA2132579A1 (en) 1995-03-24
CZ224794A3 (en) 1995-07-12
US6028090A (en) 2000-02-22
UA40590C2 (uk) 2001-08-15
NO943523L (no) 1995-03-24
US5723480A (en) 1998-03-03
JPH07179441A (ja) 1995-07-18
RU94034124A (ru) 1996-07-10
ES2132295T3 (es) 1999-08-16
CN1052227C (zh) 2000-05-10
EP0645376B1 (de) 1999-04-07
ATE178599T1 (de) 1999-04-15
ZA947405B (en) 1995-05-15
SK112194A3 (en) 1995-05-10
CN1106806A (zh) 1995-08-16
AU7305094A (en) 1995-04-06
SK282134B6 (sk) 2001-11-06
HU217980B (hu) 2000-05-28
US5561148A (en) 1996-10-01
RU2125560C1 (ru) 1999-01-27
PL180462B1 (pl) 2001-02-28
PL305144A1 (en) 1995-04-03
GR3030512T3 (en) 1999-10-29
KR100347849B1 (ko) 2002-11-16

Similar Documents

Publication Publication Date Title
KR950008493A (ko) 유착 수용체 길항물질(iii)
NO301419B1 (no) 2-okso-5-oksazolidinmetylforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse derav for fremstilling av legemidler
ZA85388B (en) Yanthine derivatives,processes for their preparation and pharmaceutical compositions containing them
YU155290A (sh) Dusikove spojine
ZA919181B (en) Oxazolopyridine derivatives,processes for preparing these and pharmaceutical compositions containing them
AU8169287A (en) New diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
ES2070994T3 (es) Profarmaco de dopamina.
ATE89547T1 (de) Dopamin-vorlaeufer.
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
IL81299A0 (en) Dihydrobenzofuran-and chromancarboxamide derivatives,their preparation and pharmaceutical compositions containing them
KR960029320A (ko) 염기성 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제
ATE32221T1 (de) 3 n-substituierte 3,4-dihydropyrimidinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen.
ES557079A0 (es) Un procedimiento para la preparacion de derivados de 1,5-benzotiazepina
PT84680A (fr) Procede de preparation de derives 1,5-benzothiazepine et de compositions pharmaceutiques les contenant
NO176018C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive S-enantiomerer av substituerte 2-aminotetraliner
KR960031457A (ko) 점착성 수용체 길항제
ES488387A1 (es) Procedimiento de preparacion de derivados condensados de pi-rrolidina
IL90179A0 (en) Glutamic acid derivatives,their preparation and pharmaceutical compositions containing them
ATE5145T1 (de) O-creatinolphosphatderivat mit therapeutischer wirkung, verfahren zu dessen herstellung und dessen pharmazeutische zusammensetzungen.
KR950032151A (ko) 점착성 수용체 길항제
KR960017662A (ko) 점착성 수용체 길항제
ES2005778A6 (es) Procedimiento para la obtencion de derivados de diisobutilxantina.
RU97102159A (ru) Этиология шизофрении и болезни паркинсона
JO1660B1 (en) Benzimidazole compounds are a therapeutically effective substitute for chlorine and processes for preparing and using them

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee